Neuroscience Investment: Challenges & Outlook

Jamie Munro BIO, Boston, MA, USA 4-7th June 2018

2

Clarivate Analytics Life Sciences

Clarivate Analytics is the global leader in providing trusted insights and analytics to accelerate the pace of innovation. Building on a heritage going back more than a century and a half, we have built some of the most trusted brands across the innovation lifecycle, including Web of Science, Cortellis, Derwent, Techstreet, CompuMark, and MarkMonitor. Today, Clarivate Analytics is a new and independent company on a bold entrepreneurial mission to help our clients radically reduce the time from new ideas to life-changing innovations.

Cortellis Competitive Intelligence Leading pipeline database for depth and breadth of content

Cortellis Deals Intelligence Rapid insights into critical deal making trends

Cortellis Regulatory Intelligence Most comprehensive regulatory content and analysis

Cortellis Clinical Trials Intelligence Broadest source of clinical trials intelligence

MetaCore Proprietary toolbox for discovery of biological pathways

Integrity & Drug Research Advisor Unique provider of multifaceted drug research content

BioWorld News Daily actionable intelligence and incisve analysis

3

Presenter & Contributors

Jamie Munro leads the Portfolio & Licensing practice at Clarivate Analytics including heading up CMR International, the R&D benchmarking service. Dr Munro has significant life science experience including over 15 years large pharma experience as well as a PhD in Finance. jamie.munro@clarivate.com

Helen Dowden is a strategic intelligence professional with more than 20 years pharmaceutical industry experience. She has a PhD in pharmacology, and is currently working as a Consultant within Clarivate’s Life Sciences Professional Services team. Helen has expertise in oncology deals analysis. helen.dowden@clarivate.com

This report contains general information only and is based on the experiences and research of Clarivate Analytics practitioners. Clarivate Analytics is not, by means of this report, rendering business, financial, investment, or other professional advice or services. This report is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Clarivate Analytics, its affiliates, and related entities shall not be responsible for any loss sustained by any person who relies on this report.

Disclaimer

Neuroscience Investment

Recent setbacks and unmet need

6

Recent late-stage AD failures

Molecule MoA Company Date

atabecestat BACE inhibitor J&J May 2018

verubecestat BACE inhibitor Merck & Co. Feb 2018/ Feb 2017

BAN2401 anti-amyloid beta mAb Biogen Dec 2017

intepirdine 5-HT6 antagonist Axovant Sciences Dec 2017/ Sep 2017

idalopirdine 5-HT6 antagonist Lundbeck/ Otsuka

Feb 2017/ Sep 2016

solanezumab anti-amyloid beta mAb (soluble Aβ)

Eli Lilly Nov 2016

BI-409306 PDE9 inhibitor Boehringer Ingelheim Sep 2016

Aβ=amyloid beta, AD=Alzheimer’s disease, mAb=monoclonal antibody

7

8

5 5

6

4

5

8

6

5

8

2

2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018

Neuroscience NME approvals by FDA

New neuroscience drugs are making it to market

Sales <$1B 80%

Other with sales >$1B 12%

Multiple sclerosis 8%

Actual/Forecast Sales for NME Neuroscience FDA Approvals

Source: FDA, Cortellis Competitive Intelligence, Clarivate analysis

* As of 24th May 2018

average

*

8

Although large unmet medical need remains for Alzheimer’s Disease

0 4,000,000 8,000,000 12,000,000 16,000,000

Duchenne Dystrophy

ALS

Huntington’s Chorea

Multiple Sclerosis

Parkinson’s Disease

Schizophrenia

Epilepsy (active treatment)

Alzheimer’s Disease

Major depressive disorder

US Prevalence

2003

2015

Year of latest NME approval

2016

2016

2017

2017

2017

2017

2017

Source: IPD, NCBI, NIH.gov health statistics, Alzheimer’s Disease Association

1 Memantine approved in Europe in 2002 and in Japan in 2011

9

Burden of disease due to dementia out-pacing most other disorders

Source: WHO Global Health Estimates Summary Tables, 2000 and 2015

Americas, 2015: Total DALYs 274,813,000 Americas, % change in DALYs 2015 vs 2000

-40%

-20%

0%

20%

40%

60%

80%

100%

120%

10

Only 31 neurological/psychiatric medicines on WHO Essential Drugs List

acetylsalicylic acid amitriptyline atracurium biperiden carbamazepine chlorpromazine clomipramine codeine diazepam fentanyl fluoxetine fluphenazine haloperidol ibuprofen lamotrigine levodopa + carbidopa

lithium carbonate lorazepam magnesium sulfate midazolam morphine neostigmine nicotine replacement therapy (NRT) paracetamol phenobarbital phenytoin propranolol risperidone suxamethonium valproic acid (sodium valproate) vecuronium

Complementary List: ethosuximide methadone pyridostigmine clozapine

Industry Overview

124

128

191 Revenues

NME Output

R&D Costs

2006 2016

Source: www.fda.gov

Revenues have outpaced the number of new medicines and R&D costs

56

45

37

38

29 29

24 27

36

20

22

18

24 26

21

30

39

27

41

45

22

46

1996 2005 2010 2011 2015 2016 2017

Source: CMR, 2017. 2006 = 100

NME Output

13

Increase in a approvals, but drugs are targeting fewer patients

US FDA CDER NME approvals Patients covered by approved indications (M)1

Source: FDA, IPD, Clarivate Analytics analysis 1 Epidemiology data from IPD and published scientific literature

21

46

2010 2017

190

154

2010 2017

14

Analysis suggests large pharma ROI has been falling year on year

Source: Deloitte, December 2017

15

But an orphan NME approval is not the end of the story

0

200

400

600

800

1000

1200

Au

g-1

4

Sep

-14

Oct

-14

No

v-1

4

Dec

-14

Jan

-15

Feb

-15

Mar

-15

Ap

r-1

5

May

-15

Jun

-15

Jul-

15

Au

g-1

5

Sep

-15

Oct

-15

No

v-1

5

Dec

-15

Jan

-16

Feb

-16

Mar

-16

Ap

r-1

6

May

-16

Jun

-16

Jul-

16

Au

g-1

6

Sep

-16

Oct

-16

No

v-1

6

Dec

-16

Jan

-17

Feb

-17

Mar

-17

Ap

r-1

7

May

-17

Jun

-17

Jul-

17

Au

g-1

7

Sep

-17

Oct

-17

No

v-1

7

Dec

-17

Nu

mb

er o

f el

igib

le U

S p

atie

nts

(1

00

0s)

Incremental growth in eligible patients for treatment with Keytruda (2014-2017)*

First FDA approval (orphan indication) for advanced melanoma refractory to ipilimumab and BRAF inhibitors and with V600 BRAF mutation

Advanced PD-L1+ NSCLC that has progressed after other treatments

Recurrent/metastatic head and neck squamous cell carcinoma (PD-L1 independent) that has progressed after platinum-containing chemotherapy

Additional indications

Source: IPD, NCI Cancer Stat Facts, and various publications * Patient number estimates are based on the prevalence of the cancer in the US. Assumptions have been made with regard to the proportion of patients eligible for Keytruda therapy (stage of disease, line of therapy, etc,)

16

0

5

10

15

20

25

30

35

0 1000 2000 3000 4000 5000 6000 7000 Sale

s fr

om

pro

du

cts

app

rove

d in

last

fiv

e ye

ars

as %

to

tal

ph

arm

a sa

les

Sales from products approved 2013-2017 ($M)

Sales from products approved in last five years (2013-2017)

Large pharma revenues have been driven by older products

Established products are driving sales

Sources: Clarivate Analytics 2018 Approvals data from Cortellis Regulatory Intelligence and FDA Product and company sales data from company Annual Reports/20-F or 10-K filings Patent expiry data from company reports (as above) and Newport Exchange rates from www.x-rates.com

0%

10%

20%

30%

40%

50%

60%

70%

80%

Off-patent sales as % total sales (2017)

No subsector has cracked the code on productivity

Source: McKinsey, Jan 2017

18

Growth forecast for global Neuroscience market versus Oncology

1 “Central Nervous System (CNS) Therapeutic Market Analysis By Disease (Neurovascular, Trauma, Mental Health, Degenerative Disorder [Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis], Infections, Cancer), & Segment Forecasts, 2016 – 2025”, Grand View Research, July 2017 2 “Top 20 pharma companies by CNS sales”, PMLive, http://www.pmlive.com/top_pharma_list/cns_revenues (data from Global Data – includes Rx and generics) 3 “Top 20 pharma companies by oncology sales”, PMLive, http://www.pmlive.com/top_pharma_list/oncology_revenues (data from Global Data – includes Rx and generics) 4 “Neurology Devices Market Analysis By Product (Neurostimulation, Interventional Neurology, CSF Management, Spinal Cord Stimulation, Deep Brain Stimulation, Embolization, Neurovascular Catheters, Cerebral Angioplasty & Stents, CSF Shunts, Ultrasonic Aspirators, Stereotactic Systems) And Segment Forecasts To 2022”, Grand View Research, May 2016

Forecast neuroscience sales growth of top 20 pharmas with CNS sales ($M)2

0

20,000

40,000

60,000

80,000

100,000

120,000

140,000

160,000

180,000

200,000

0

20,000

40,000

60,000

80,000

100,000

120,000

140,000

160,000

180,000

200,000

Forecast oncology sales growth of top 20 pharmas with oncology sales ($M)2

19

Regulatory environment challenging

‘Expedited review’ refers to EMA ‘Accelerated Assessment’ and FDA/PMDA ‘Priority Review. Approval time is calculated from the date of submission to the date of approval by the agency. This time includes agency and company time. EMA approval time includes the EU Commission time. ‘Nervous System’ includes anaesthetics, analgesics, antiepileptics, anti-parkinson drugs, psycholeptics, psychoanaleptics, and “other nervous system” Data includes new active substances only

(a) Median approval time (days): 2013-2017

(b) % approvals with expedited review: 2013-2017

(c) Approval time by TA for 6 regulatory authorities: 2013-2017 (ordered by fastest agency median approval time within each TA)

0

100

200

300

400

500

600

EMA FDA PMDA

Cardiovascular Anti-infective Anticancer

Alimentary Nervous System

0%

20%

40%

60%

80%

100%

EMA FDA PDMA

Cardiovascular Anti-infective Anticancer

Alimentary Nervous System

20

Neuroscience success rates lower than most other therapy areas, especially in early development

Source: CMR. Probability of Launch from stage shown for Active Substances for Decisions Made 2010-2016 by Therapeutic Area, using Progression Decision Methodology

Probability of Launch by Therapeutic Area: 2010-20161

11

%

17

%

30

%

70

%

86

%

7%

9%

23

%

58

%

95

%

5%

7%

18

%

77

%

93

%

5%

7%

16

%

86

%

10

0%

4%

6%

12

%

55

%

10

0%

2%

3%

9%

43

%

10

0%

1%

2%

7%

48

%

10

0%

First tox dose First human dose First patient dose First pivotal dose First submission

Anti-infective Anticancer Alimentary/metabolism Respiratory Musculoskeletal Cardiovascular Nervous system

21

Illustrative Implications

o Assuming costs of one successful NS drug of $365m

o Would yield total costs of $4.6bn including costs of failure

o Assuming R&D: Sales of 25% and hub costs of $0.4bn would require revenues of $20bn

o Would require a blockbuster with PYS of $1.8bn+

Neuroscience Investment

General Snapshot

23

Number of neurological medicines in development increased in last 3 years, driven by cancer and Alzheimer’s disease. Companies back out of pain and multiple sclerosis

58 59

94

31

46

22 21 19

33

20 20 12 8 6 4

95 92

76

46 52

36 34 34 29 27 26 20

10 7 6

2015 2018

+64%

-12%

-19%

+56%

Source: Adapted from PhRMA “Neurological Medicines in Development” reports, 2015 and 2018

24

Neuroscience remains an active area for R&D

Oncology

Immune/ Inflam

Neurology

Infection Gastro-intestinal

Endocrine/ Metabolic

Respiratory

Hematologic

Genito-urinary

Cardio

Derm

Musculo-skeletal

Ophthalm Tox/Intox

Drug pipeline by TA and highest development stage Drug pipeline breakdown by TA

0% 20% 40% 60% 80% 100%

Toxicity/Intox

Ophthalm

Musculoskeletal

Dermatologic

Cardiovascular

Genitourinary

Hematologic

Respiratory

Endo/Metabolic

Gastrointestinal

Infection

Neurology

Immune/Inflam

Oncology

Discovery Phase 1 Phase 2 Phase 3 Launched

Data extracted from Cortellis for Competitive Intelligence and cover all development programs captured as of Dec 31, 2017

25 Most research directed at neurological disease Greatest focus on pain and Alzheimer’s disease

Pain 19%

Alzheimer's disease 14%

Neuropathy 7%

Parkinson's disease 7%

Neuromscular disease

7%

Cerebrovascular disease

5%

Multiple sclerosis 5%

Movement disorders

4%

Epilepsy 3%

Huntington's chorea 2%

Other neurological 10%

Anxiety 2%

Drug dependence 4%

Mood disorder 4%

Psychotic disorder 4%

Other psychiatric 2%

Psychiatric disorders 15% : Neurological disease 85%

Data extracted from Cortellis for Competitive Intelligence. Programs with an active indication of neurological disease or psychiatric disorder in development (discovery through registration) as of Mar 2, 2018

26

Pharma companies with core neuroscience R&D: 2008 vs 2018

Company 2008 → 2018

Abbott/AbbVie ↑

Allergan X ↑

Amgen ↑

Biogen ↑

Novartis ↑

Roche ↑

Takeda ↑

Johnson & Johnson -

UCB -

AstraZeneca ↓ X

Bayer X - X

Bristol-Myers Squibb ↓ X

GlaxoSmithKline ↓ X

Eli Lilly ↓

Merck & Co ↓

Pfizer ↓ X

Sanofi ↓

Wyeth ↓ X

BUILD/ENTER

REDUCE/EXIT

MAINTAIN

27

Other top-ranked biopharmaceutical companies and neuroscience interest

Company R&D1 Neuro ?

Celgene 3,177

Gilead 2,584 X

Regeneron 1,547 X

Shire 1,324

Vertex 1,018

Incyte 879 X

Alexion 798

BioMarin 442

Seattle Genetics 346 X

Alkermes 308

Alnylam 273 X

Ionis 246

Agios 215 X

Tesaro 211 X

Alder 208

Horizon 194

Nektar 187

1 Q3 2017 total R&D spend (USD M) ADHD=Attention deficit disorder, AD=Alzheimer’s disease, BPD= Borderline personality disorder, IVH=Intraventricular haemorrhage, MS=Multiple sclerosis, CNP2=Neuronal ceroid lipofuscinosis type 2

28

US FDA CDER NME approvals resulting from licensing/acquisition (2010-2017)

External assets make up a significant % of approvals

0%

10%

20%

30%

40%

50%

60%

70%

80%

2010 2011 2012 2013 2014 2015 2016 2017

Origin (A or L)

Neuroscience Investment

Neuroscience deal-making

30 Neuroscience is an active area for deal-making, although well below the level for oncology

Number of buy-side transactions by therapy area for top pharma dealmakers J&

J

Me

rck

BM

S

Take

da

No

vart

is

Me

rck

KG

aA

Ro

che

San

ofi

BI

Ab

bvi

e

AZ

Dai

ich

i

Cel

gen

e

Pfi

zer

Lilly

On

o

Am

gen

Bio

gen

Eisa

i

Ots

uka

Serv

ier

Shir

e

Bay

er

Alle

rgan

Ast

ella

s

GSK

Gile

ad

Sum

ito

mo

Shio

no

gi

Teva

TOTA

L

Oncology 7 13 19 8 5 13 8 1 3 4 3 6 4 3 1 5 3 4 1 2 2 2 1 118

Neuroscience 5 2 2 1 1 1 2 1 1 1 2 1 2 4 1 3 1 1 2 1 1 2 38

Immune/Inflam 2 1 1 3 1 2 4 2 1 1 3 1 1 1 24

Infectious 4 1 3 1 1 4 1 1 1 3 3 1 1 25

Gastro 2 6 1 1 3 1 1 1 1 2 19

Diversified 5 1 1 1 1 1 1 1 1 1 14

Endo/Met 2 1 4 2 2 1 12

Ophthalm 3 2 1 2 1 1 1 11

Cardiology 2 2 2 1 1 1 9

Musculoskel 5 1 1 1 8

Respiratory 1 1 3 1 6

Hematology 1 4 5

Dermatology 1 1 1 3

Source: Cortellis Deals Intelligence Covers key transactions types, M&As, Licenses/joint ventures, Research-only deals, and Other (Asset Purchases, Equity Stakes, Spin-outs), with identifiable therapeutic focus areas. Covers all technologies. Not shown: Other, Genitourinary, Toxicity, Unknown and Not Applicable therapy area deals. Companies are those among the top 50 pharmaceutical companies who announced 5 or more buyside transactions in 2017

31

Neuroscience deal volume has risen steadily, although value is variable

Trends in Neuroscience Licensing/JV/Research only deals

Source: Cortellis Deals Intelligence Clarivate analysis, BioWorld

0

2000

4000

6000

8000

10000

12000

0

20

40

60

80

100

120

140

160

180

2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 (4 mts)

Tota

l dea

l val

ue

($M

)

No

. Lic

/JV

/Rsc

h d

eals

No. Deals Total value

32

0

10

20

30

40

50

60

Pe

rce

nt

bre

akd

ow

n o

f M

&A

s b

y TA

2016 2017

Analysis covers M&A transactions with an identifiable core therapeutic focus. Not shown are TAs for which there were ≤5 M&As announced in 2017: Hematology, Gastroenterology, Toxicity, Respiratory & Endo/Met

Recent M&A activity is down

Volume Breakdown by Rx Area of 2016 vs. 2017 M&As with known therapeutic focus

Source: Cortellis Deals Intelligence, Clarivate analysis

33

Meanwhile, level of VC investment has increased significantly

Neurology 92%

Psychiatry 8%

Neurology vs Psychiatry: Total 2016 US VC investment of $689M

Source: “Emerging Therapeutic Company Investment and Deal Trends: 2007--2016”, BIO Industry Analysis, BioWorld’s BioPharma Financings Report Neurology/Psychiatric Market Report - 2017

0

1000

2000

3000

4000

5000

6000

7000

2007-2011 2012-2016

Value of neuroscience US VC investments ($M)

Neuroscience Oncology

0

5000

10000

15000

20000

25000

Biopharma Financing in 2017 by Therapeutic Area

IPOs & Follow-Ons Venture Funding Public- Other

34

Similar message with regard to government funding

NIH funding ($M) for Various Research, Condition, and Disease Categories (RCDC)

Disease Area FY 2013 FY 2017 (enacted)

Cancer 5,274 6,032 +14%

Neuroscience 5,340 6,743 +26%

0

200

400

600

800

1,000

1,200

1,400

1,600

1,800

NIH funding ($M) for Alzheimer's Disease (incl. AD-related dementias)

Source: NIH

35

Promising forthcoming neuroscience therapies1

Molecule Company Phase Launch

inotersen (antisense RNA modulator) Ionis Pharmaceuticals Filed Launch 2018

NurOwn® (neurotrophic factor-producing mesenchymal stem cell therapy)

Brainstorm Cell Therapeutics P3 Canada 2018

APL-130277 (apomorphine sublingual film) Aquestive Therapeutics/ Sunovion Pharmaceuticals

Filed Launch 2019

AVXS-101 (gene therapy) AveXis P3 Launch 2019

NKTR-181 (opioid mu receptor agonist) Nektar Therapeutics P3 Launch 2019

ZX008 (fenfluramine low dose) Zogenix P3 Launch 2019

fosmetpantotenate (prodrug) Retrophin P3 Launch > 2019

galcanezumab (anti-CGRP antibody) Eli Lilly P3 2018 for migraine (2020 for cluster)

fremanezumab (anti-CGRP antibody) Teva Pharmaceuticals P3 2018 for migraine (> 2020 for cluster)

rapastinel (NMDA partial agonist) Allergan P3 Launch > 2020

Toca 511 & Toca FC (vocimagene amiretrorepvec flucytosine gene therapy)

Tocagen P3 Launch > 2020

esketamine (NMDA antagonist) Janssen P3 Launch > 2021

aducanumab (anti-beta-amyloid antibody) Biogen/Eisai P3 Launch > 2022

1Late-stage development programmes with US FDA Fast Track designation

*

* Consensus forecast > $1Bn by 2023

*

36

Neurological devices

0

200

400

600

800

1000

1200

1400

0

10

20

30

40

50

60

70

Med

ian

ap

pro

val t

ime

(day

s)

No

. ap

pro

vals

US FDA Medical Device Approvals by Advisory Committee: 2013-2017

Total no. approvals Median approval time (days)

Source: Cortellis Regulatory Intelligence, Clarivate analysis

37

o Machine learning is helping advance the prediction of patterns from complex data sets.

o Hardware and computational advances are also generating enhanced visualization in medical imaging.

o The proliferation of smartphones and the advent of linked wearable devices are facilitating data collection and promoting cost-effectiveness of clinical trials.

o Continual real-time monitoring of patients will open up the possibility of linking clinical outcomes to real-world patient behaviour.

o Progress is being made toward continuous, auto-correcting, minimally-invasive, or “closed loop” therapies for neurological disease.

Digital health

Neuroscience Investment

AD development and learnings from oncology

39

Alzheimer’s clinical research heavily concentrated on beta amyloid

59

26

20 20

8 7 5 5 5 4 3 3 3 3 3 2 2 2 2 2 2 2 2 2 2 2

48

Source: Cortellis Competitive Intelligence. All molecules with active clinical (P1 through registration) projects directed at Alzheimer’s Disease included

40

Oncology has benefited from a decade of prioritized investment

2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

Increase in novel oncology FDA approvals

CDER oncology NME approvals CBER oncology treatment approvals

1Cortellis Competitive Intelligence consensus sales forecasts 2American Cancer Society 3Cancer Research UK

Nu

mb

er o

f ac

tive

su

bst

ance

s

Immuno-oncology is increasing with 350 compounds in active development globally

157

47 39

8 1

7

Discovery Phase I Phase II Phase III Registered Launched

Source: Clarivate Analytics Cortellis Competitive Intelligence, Data extracted in June 2017

Immuno-oncology activity is increasing with ~250 compounds in active development

Compound Target Phase

elotuzumab CD2 Launched

ipilimumab CTLA4 Launched

atezolizumab PD-L1 Launched

nivolumab PD-1 Launched

pembrolizumab PD-1 Launched

durvalumab PD-L1 Launched

avelumab PD-L1 Launched

42

o Despite high profile exits of some large pharma companies, neuroscience investment remains strong

o An effective Alzheimer’s therapy remains the holy grail, but there are reasons for optimism

o Advances in Alzheimer biomarkers

o In preventing neurodegeneration, there is clear rationale for earlier treatment. Such studies now underway

o Current clinical repertoire biased toward Aβ hypothesis: greater diversity of experimental approaches required

o Therapies aimed at nerve regeneration versus degeneration prevention have begun to enter clinical testing

Summary

1 Yanagisawa K et al, Nature 554: 249–254, 8 February 2018

Powering life sciences innovation with trusted content, analytics & technology.

clarivate.com/contact-us

Appendix

Clarivate Analytics is the global leader in providing trusted insights and analytics to accelerate the pace of innovation. Building on a heritage going back more than a century and a half, we have built some of the most trusted brands across the innovation lifecycle, including Web of Science, Cortellis, Derwent, CompuMark, MarkMonitor and Techstreet. Today, Clarivate Analytics is a new and independent company on a bold entrepreneurial mission to help our clients radically reduce the time from new ideas to life-changing innovations.

• Biopharmaceutical

• benchmarking

• Landscaping

• Dashboards

• Ad hoc reports

• Strategy

• Commercial Assessments

• Prioritisation

• Partner ID & DD

• Deals intelligence

• Asset re-profiling

Business Development

& Licensing

Strategy and Portfolio

Management

CMR Competitive Intelligence

Portfolio & Licensing spans a number of areas

46

CMR International

• The Centre for Medicines Research International (CMR) is a Clarivate Analytics business

• With more than 20 years of experience of Biopharmaceutical Benchmarking

• CMR works closely with 80% of Top 20 & 76% of Top 50 pharmaceutical companies (measured by R&D expenditure) to assess R&D & Clinical productivity and provide actionable data and insights

• CMR currently runs a number of benchmarking programmes

47

48

Cortellis: Unrivaled content coverage and reliability

Proprietary and comprehensive content

Cortellis Competitive Intelligence

Leading pipeline database for depth and breadth of content

Cortellis Deals Intelligence

Rapid insights into critical deal making trends

Cortellis Regulatory Intelligence

Most comprehensive regulatory content and analysis offering

Cortellis Clinical Trials Intelligence

Broadest source of clinical trials intelligence

MetaCore

Proprietary toolbox for discovery of biological pathways

Integrity & Drug Research Advisor

Unique provider of multifaceted drug research content

Clinical trial registries

Patents

Deals

Regulatory

Pharmacology

Annual reports & brokers analysis

Companies websites

Animal models

Sou

rces

of

co

nte

nt

Simplify Synthesize

Organize

Expert insight and pharma intelligence for competitive analysis. Track your closest competitors - Drug pipeline, deals, patents, global conferences, and company content, along with the latest industry news and press releases, are all brought together in an intuitive intelligence tool. From one source, see your chosen indications, actions, and companies in context – speeding up decision making by providing the exact information you’re looking for the first time. Competitive landscape from discovery stages - Benchmark competitors/market leaders and identify the competitive landscape earlier than any other pipeline database. Flexibility - Moving along with your needs, our high-quality content is provided via a web portal, data feeds and web services APIs.

Cortellis Competitive Intelligence

Deal-making is the lifeblood of the industry and a central focus for company growth, getting drugs/devices to market and overall success. Effective deals are crafted from a mix of good science, creative approaches to relationships and thorough research on the competition – starting with data from a source like Cortellis Deals Intelligence. Cortellis Deals Intelligence helps you: Understand a set of deals in minutes, not hours Find precise comparables Create your own custom analysis Quickly identify potential deal partners by therapy area, mechanism, technology and stage of development Gain even deeper insights into biopharma alliances

Cortellis Deals Intelligence

Powering life sciences innovation with trusted content, analytics & technology.

clarivate.com/contact-us